Genzyme and Relational Investors: Science and Business Collide?
The chairman and CEO of the Genzyme Corporation, one of the country's top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.
2020 ◽
Vol 158
(04)
◽
pp. 345-350
2005 ◽
Vol 22
(3)
◽
pp. 29-38
Keyword(s):
2018 ◽
Vol 3
(1)
◽
Keyword(s):